Illumina, Inc. (ILMN)

Last Price: 273.00 (2020-09-23)

Company Description

Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $3.54B
Net Income (Most Recent Fiscal Year) $1.00B
PE Ratio (Current Year Earnings Estimate) 61.23
PE Ratio (Trailing 12 Months) 45.59
PEG Ratio (Long Term Growth Estimate) 8.75
Price to Sales Ratio (Trailing 12 Months) 11.70
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 8.65
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 32.62
Pre-Tax Margin (Trailing 12 Months) 26.31%
Net Margin (Trailing 12 Months) 20.67%
Return on Equity (Trailing 12 Months) 19.13%
Return on Assets (Trailing 12 Months) 12.08%
Current Ratio (Most Recent Fiscal Quarter) 3.76
Quick Ratio (Most Recent Fiscal Quarter) 3.37
Debt to Common Equity (Most Recent Fiscal Quarter) 0.14
Inventory Turnover (Trailing 12 Months) 2.49
Book Value per Share (Most Recent Fiscal Quarter) $31.38
Earnings per Share (Most Recent Fiscal Quarter) $0.62
Earnings per Share (Most Recent Fiscal Year) $6.57
Diluted Earnings per Share (Trailing 12 Months) $4.68
Stock
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Common Shares Outstanding 146.00M
Free Float 145.44M
Market Capitalization $39.20B
Average Volume (Last 20 Days) 1.80M
Beta (Past 60 Months) 0.88
Percentage Held By Insiders (Latest Annual Proxy Report) 0.38%
Percentage Held By Institutions (Latest 13F Reports) 92.89%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%